Encapsulation of paclitaxel in macromolecular nanoshells

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Paclitaxel is a crucial chemotherapy drug for breast cancer but its delivery is limited by adverse side effects from solvents like Cremophor EL.
• Developing effective drug delivery systems is essential to improve therapeutic outcomes and reduce toxicity.
• Nanoparticle-based drug delivery offers potential for targeted therapy and controlled release.

Purpose of the Study:

• To develop and characterize paclitaxel-loaded core-shell nanoparticles using electrostatic layer-by-layer self-assembly.
• To evaluate the in vitro anticancer activity of these novel nanoparticles against a human breast carcinoma cell line (MCF-7).
• To assess the potential of this system as an alternative drug delivery vehicle for paclitaxel, avoiding Cremophor EL.

Main Methods:

• Solid core paclitaxel nanoparticles were prepared via nanoprecipitation (153 +/- 28 nm).
• A polymeric nanoshell was constructed using electrostatic layer-by-layer assembly of poly(allylamine hydrochloride) and poly(styrene-4-sulfonate).
• In vitro cytotoxicity and cellular effects (cell cycle, morphology, cytoskeleton) were assessed on MCF-7 cells.

Main Results:

• Paclitaxel core-shell nanoparticles successfully induced cell cycle arrest in the G2/M phase in MCF-7 cells after 24 and 48 hours.
• Significant morphological changes, including nuclear fragmentation and loss of cell-cell contacts, were observed.
• Abnormal microtubule and actin cytoskeleton morphology indicated cellular response to the paclitaxel nanoparticles.

Conclusions:

• The electrostatic layer-by-layer self-assembly technique is effective for creating paclitaxel core-shell nanoparticles.
• These nanoparticles demonstrate potent in vitro anticancer activity against breast cancer cells.
• This core-shell nanoparticle system represents a promising Cremophor EL-free delivery strategy for paclitaxel in cancer therapy.